Who owns BIOCRYST PHARMACEUTICALS INC?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BCRX from SEC Form 13F filings across 319 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 319 institutions disclosed 261.6M shares of BIOCRYST PHARMACEUTICALS INC worth $2.61B — about 102.8% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
319
13F holders
$2.61B
value, 2026 filers
102.8%
of shares outstanding (261.6M sh)
59
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BCRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 23.9M | $238.9M | 0.0% | 9.4% | +5.5% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 15.8M | $158.3M | 1.4% | 6.2% | 0.0% |
| 3 | STATE STREET CORP | 15.2M | $151.9M | 0.0% | 6% | +24.4% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 15.1M | $151.0M | 1.6% | 5.9% | +0.4% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 11.4M | $113.6M | 0.0% | 4.5% | +2.1% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11.1M | $111.4M | 0.0% | 4.4% | -0.9% |
| 7 | TCG Crossover Management, LLC | 11.0M | $110.2M | 2.6% | 4.3% | 0.0% |
| 8 | PERCEPTIVE ADVISORS LLC | 10.3M | $103.1M | 1.5% | 4.1% | +38.7% |
| 9 | Jupiter Topco LLCNEW | 9.5M | $95.3M | 0.0% | 3.7% | new |
| 10 | Vestal Point Capital, LP | 8.3M | $83.0M | 1.9% | 3.3% | +18.1% |
| 11 | TWO SIGMA INVESTMENTS, LP | 6.8M | $67.8M | 0.0% | 2.7% | +6.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 6.2M | $62.5M | 0.0% | 2.5% | +8.0% |
| 13 | Aberdeen Group plc | 5.3M | $53.1M | 0.1% | 2.1% | +5.4% |
| 14 | UBS Group AG | 5.1M | $50.8M | 0.0% | 2% | +2.7% |
| 15 | BANK OF AMERICA CORP /DE/ | 4.8M | $48.0M | 0.0% | 1.9% | -5.7% |
| 16 | GOLDMAN SACHS GROUP INC | 4.5M | $44.8M | 0.0% | 1.8% | +90.9% |
| 17 | Frazier Life Sciences Management, L.P. | 4.0M | $40.1M | 0.9% | 1.6% | 0.0% |
| 18 | Nuveen, LLC | 4.0M | $40.1M | 0.0% | 1.6% | +4.9% |
| 19 | MILLENNIUM MANAGEMENT LLC | 3.4M | $33.9M | 0.0% | 1.3% | +1708.4% |
| 20 | GW&K Investment Management, LLC | 3.2M | $31.7M | 0.2% | 1.2% | -2.1% |
| 21 | JANE STREET GROUP, LLC | 2.8M | $27.6M | 0.0% | 1.1% | +343.7% |
| 22 | DIMENSIONAL FUND ADVISORS LP | 2.7M | $27.2M | 0.0% | 1.1% | +1.0% |
| 23 | Fisher Asset Management, LLC | 2.6M | $26.0M | 0.0% | 1% | -4.7% |
| 24 | RENAISSANCE TECHNOLOGIES LLC | 2.5M | $25.3M | 0.0% | 1% | +225.7% |
| 25 | Kynam Capital Management, LP | 2.5M | $25.2M | 1.4% | 1% | -55.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.